Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate

Xiliu Chen; Di Liu; Dongliang Yang; Xin Zheng

doi:10.14218/JCTH.2020.00129

Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate

J Clin Transl Hepatol. 2021 Apr 28;9(2):269-273. doi: 10.14218/JCTH.2020.00129. Epub 2021 Apr 9.

Authors

Xiliu Chen^{1

2}, Di Liu³, Dongliang Yang^{1

2}, Xin Zheng^{1

2}

Affiliations

¹ Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
² Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, Hubei, China.
³ Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic continues worldwide. We report here two cases of chronic hepatitis B patients with acute respiratory syndrome coronavirus 2 infection treated with tenofovir disoproxil fumarate who demonstrated a favorable outcome. This report adds some evidence that concurrent HBV infection may not worsen COVID-19 infection and tenofovir disoproxil fumarate treatment may have partial positive effect on COVID-19 rapid recovery.

Keywords: COVID-19; Chronic hepatitis B; SARS-CoV-2; Tenofovir disoproxil fumarate.

Publication types

Case Reports